Zobrazeno 1 - 10
of 434
pro vyhledávání: '"1 receptor agonist"'
Autor:
Mahmoud Balata, Marc Ulrich Becher
Publikováno v:
BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background & objectives Obesity is a common comorbidity in heart failure, yet effective pharmacological options for weight loss in these patients are limited. Semaglutide, a glucagon-like peptide 1 receptor agonist, has shown promise for wei
Externí odkaz:
https://doaj.org/article/78c6c558cc3a4a8a977cc08ef214cfc7
Autor:
Hae Young Lee, Seung-Hyun Ko, Sungjoon Park, Kyuho Kim, Song-Yi Kim, In-Jeong Cho, Eun Joo Cho, Hyeon Chang Kim, Jae-Hyeong Park, Sung Kee Ryu, Min Kyong Moon, Sang-Hyun Ihm, the Korean Society of Hypertension
Publikováno v:
Clinical Hypertension, Vol 30, Iss 1, Pp 1-16 (2024)
Abstract Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of
Externí odkaz:
https://doaj.org/article/aabf41d4848d497191aab60333853294
Autor:
Tetsuaki Inokuchi, Yoshihide Fukumoto, Gendai Lee, Yoshifumi Yokomizo, Kokichi Tanaka, Michiko Chosa, Masaru Doi, Noboru Tamaki, Seiichi Goto, Kojiro Ichikawa, Kazuo Kobayashi
Publikováno v:
Journal of Diabetes Investigation, Vol 15, Iss 9, Pp 1202-1210 (2024)
ABSTRACT Introduction Glucagon‐like peptide 1 receptor agonists (GLP1Ras) have emerged as pivotal agents in diabetes management and organ protection. However, their use is limited due to the necessity for injectable administration. The advent of th
Externí odkaz:
https://doaj.org/article/98534f7f8829407095660795b31ba776
Autor:
Christopher S. Freet, Brianna Evans, Timothy R. Brick, Erin Deneke, Emily J. Wasserman, Sarah M. Ballard, Dean M. Stankoski, Lan Kong, Nazia Raja-Khan, Jennifer E. Nyland, Amy C. Arnold, Venkatesh Basappa Krishnamurthy, Julio Fernandez-Mendoza, H. Harrington Cleveland, Adam D. Scioli, Amanda Molchanow, Amy E. Messner, Hasan Ayaz, Patricia S. Grigson, Scott C. Bunce
Publikováno v:
Addiction Science & Clinical Practice, Vol 19, Iss 1, Pp 1-13 (2024)
Abstract Background Despite continuing advancements in treatments for opioid use disorder (OUD), continued high rates of relapse indicate the need for more effective approaches, including novel pharmacological interventions. Glucagon-like peptide 1 r
Externí odkaz:
https://doaj.org/article/85a4d926fdcd4c8dbbfc6c19cf3a5ca6
Publikováno v:
Diabetology, Vol 5, Iss 3, Pp 234-245 (2024)
The prevalence of obesity in adults with type 1 diabetes is increasing and reflects the rates of the general adult population. The coexistence of overweight or obesity and type 1 diabetes poses a major challenge to effective glycemic and weight manag
Externí odkaz:
https://doaj.org/article/69e29db473ed400fa9e56e2d64041b78
Publikováno v:
ESC Heart Failure, Vol 11, Iss 3, Pp 1647-1656 (2024)
Abstract Aims The study aims to provide comprehensive evidence for the selection of agents in type 2 diabetes mellitus (T2DM) patients with cardiovascular risk and summarize the lasted evidence for the cardiovascular effects of sodium glucose cotrans
Externí odkaz:
https://doaj.org/article/5509a21845ba41ccb1191149c0c6d527
Autor:
Sean A. Newsom, Matthew M. Robinson
Publikováno v:
Physiological Reports, Vol 12, Iss 11, Pp n/a-n/a (2024)
Abstract Regular exercise and antihyperglycemic drugs are front‐line treatments for type‐2 diabetes and related metabolic disorders. Leading drugs are metformin, sodium‐glucose cotransporter‐2 inhibitors, and glucagon‐like peptide 1 recepto
Externí odkaz:
https://doaj.org/article/e765697ce5ab48b68063d60e2e32c8dd
Autor:
Takashi Asano, Hiroki Takemoto, Tomoya Horita, Tomohiro Tokutake, Naotaka Izuo, Takatoshi Mochizuki, Atsumi Nitta
Publikováno v:
Neuropsychopharmacology Reports, Vol 43, Iss 4, Pp 505-512 (2023)
Abstract Cannabis withdrawal syndrome (CWS) in humans is characterized by various somatic symptoms, including sleep disturbances. In the present study, we investigated sleep alterations in mice after the cessation of arachidonylcyclopropylamide (ACPA
Externí odkaz:
https://doaj.org/article/74f758ae35bc4a98aadbbcb213027eae
Autor:
Giuseppe Lisco, Anna De Tullio, Olga Disoteo, Giuseppina Piazzolla, Edoardo Guastamacchia, Carlo Sabbà, Vincenzo De Geronimo, Enrico Papini, Vincenzo Triggiani
Publikováno v:
Endocrine Connections, Vol 12, Iss 11, Pp 1-7 (2023)
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have changed considerably the management of type 2 diabetes (T2D). However, recently published data from retrospective cohort studies suggest that chronic exposure to GLP-1RAs in T2D may increase t
Externí odkaz:
https://doaj.org/article/bdc54c1d61ab4e9fb5d717056b3d2fc8
Autor:
Sarah L Anderson, Joel C Marrs
Publikováno v:
Drugs in Context, Vol 12, Pp 1-8 (2023)
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 re
Externí odkaz:
https://doaj.org/article/ccf24655131449448b36d7bef1262547